AI English summary of an SEC filing — figures as filed
Insulet PODDInsulet announced on September 16, 2025 that it appointed Flavia H. Pease to succeed Ana M. Chadwick as Executive Vice President and Chief Financial Officer. Pease will assume the role on September 30, 2025, and Chadwick will remain with the Company as a Senior Advisor.
Key points
AI summaryInsulet announced on September 16, 2025 that it appointed Flavia H. Pease to succeed Ana M. Chadwick as Executive Vice President and Chief Financial Officer. Pease will assume the role on September 30, 2025, and Chadwick will remain with the Company as a Senior Advisor.
The Company said Pease will resign from the Board of Directors on the day she begins employment and served as a director and Audit Committee member since January 2024. Pease has been Chief Financial Officer of Charles River Laboratories since 2022 and worked at Johnson & Johnson from 1998 to 2022.
Insulet said Pease's annual base salary will be $715,000, her target annual bonus opportunity will be 70% of her annual base salary, and she will receive a cash sign-on award of $1,325,000, a prorated annual equity award with a target aggregate grant date fair value of $762,500, and an Equity Sign-On Award with a target aggregate grant date fair value of $3,000,000.
The Company said it expects to enter into a Severance Agreement with Chadwick that includes a one-time cash payment equal to the value of equity scheduled to vest on May 1, 2026. It also said it expects Q3 2025 total revenue growth to exceed its previously issued guidance.
Summary
AI-writtenAnalysis scope · Filing body and confirmed press-release exhibitWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call.
Chief Financial Officer Transition and Effective Date
Insulet announced on September 16, 2025 that it appointed Flavia H. Pease to succeed Ana M. Chadwick as Executive Vice President and Chief Financial Officer. Pease will assume the role on September 30, 2025, and Chadwick will remain with the Company as a Senior Advisor.
Source · Based on the filing body and exhibits
Pease's Board Resignation and Background
The Company said Pease will resign from the Board of Directors on the day she begins employment and served as a director and Audit Committee member since January 2024. Pease has been Chief Financial Officer of Charles River Laboratories since 2022 and worked at Johnson & Johnson from 1998 to 2022.
Source · Based on the filing body and exhibits
Pease Offer Letter Compensation Terms
Insulet said Pease's annual base salary will be $715,000, her target annual bonus opportunity will be 70% of her annual base salary, and she will receive a cash sign-on award of $1,325,000, a prorated annual equity award with a target aggregate grant date fair value of $762,500, and an Equity Sign-On Award with a target aggregate grant date fair value of $3,000,000.
Source · Based on the filing body and exhibits
Chadwick Departure Terms and Q3 Outlook
The Company said it expects to enter into a Severance Agreement with Chadwick that includes a one-time cash payment equal to the value of equity scheduled to vest on May 1, 2026. It also said it expects Q3 2025 total revenue growth to exceed its previously issued guidance.
Source · Based on the filing body and exhibits
AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.
Original filing
The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.
Loading the filing text…